+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07613424

Multicenter Prospective Study Evaluating MET Concordance and Tumor Gene Profiling in First-Line Non-Small Cell Lung Cancer

Led by AstraZeneca · Updated on 2026-10-26

1000

Participants Needed

51

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the agreement between four different test methods and a reference assay for MET overexpression in patients with untreated non-small cell lung cancer NSCLC. The study focuses on treatment-nave patients with unresectable locally advanced, metastatic, or recurrent NSCLC. It is a multicenter, prospective study sponsored by AstraZeneca, aiming to improve understanding of tumor gene profiling and MET concordance. Participants undergo next-generation sequencing NGS testing initially to determine their EGFR mutation status. Based on these results, participants are assigned to one of three cohorts those with specific EGFR mutations, those without actionable genomic alterations, and those with other actionable genomic alterations. Additional diagnostic tests such as MET IHC testing, PD-L1, and Her2 testing are performed for participants in the first cohort. During the study, participants provide tissue samples collected after diagnosis but before any antitumor treatment. The research team analyzes various biomarkers and treatment patterns up to 90 days after the last patient in. Participants are monitored through these tests and gene profiling to assess the concordance of different diagnostic methods. The total participation duration aligns with the study completion date in March 2027.

CONDITIONS

Brief Title

A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here